These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27228176)

  • 41. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
    Silva RR
    Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
    [No Abstract]   [Full Text] [Related]  

  • 42. [Use of methylphenidate in adults with attention deficit disorder with hyperactivity].
    Gauillard J; Castelnau C; Vacheron-Trystram MN; Cheref S; Caroli F
    Encephale; 1997; 23(4):251-6. PubMed ID: 9417389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment.
    Koneski JA; Casella EB
    Arq Neuropsiquiatr; 2010 Feb; 68(1):107-14. PubMed ID: 20339664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome.
    Hechtman L; Greenfield B
    Paediatr Drugs; 2003; 5(12):787-94. PubMed ID: 14658920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 46. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711
    [No Abstract]   [Full Text] [Related]  

  • 47. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visual fields in children with attention-deficit/hyperactivity disorder before and after treatment with stimulants.
    Ghanizadeh A
    Acta Ophthalmol; 2010 Mar; 88(2):e56. PubMed ID: 19508459
    [No Abstract]   [Full Text] [Related]  

  • 49. Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
    Kara T; Akaltun İ
    J Clin Psychopharmacol; 2017 Aug; 37(4):484. PubMed ID: 28492426
    [No Abstract]   [Full Text] [Related]  

  • 50. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
    Lewis H; Lewis J
    Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder.
    Kummer A; Teixeira A
    Australas Psychiatry; 2008 Dec; 16(6):458-9. PubMed ID: 19034996
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.
    van der Feltz-Cornelis CM; Aldenkamp AP
    Epilepsy Behav; 2006 May; 8(3):659-62. PubMed ID: 16504592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term effects of ADHD medication on adult height: results from the NESARC.
    Peyre H; Hoertel N; Cortese S; Acquaviva E; Limosin F; Delorme R
    J Clin Psychiatry; 2013 Nov; 74(11):1123-4. PubMed ID: 24330902
    [No Abstract]   [Full Text] [Related]  

  • 54. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR; Scott LJ
    Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.
    Conners CK
    J Atten Disord; 2002; 6 Suppl 1():S17-30. PubMed ID: 12685516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The answerable question and a hierarchy of evidence.
    Hamilton J
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):596-600. PubMed ID: 15908843
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone.
    Spencer TJ; Bhide P; Zhu J; Faraone SV; Fitzgerald M; Yule AM; Uchida M; Spencer AE; Hall AM; Koster AJ; Biederman J
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28640990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
    Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Question 2 Should a child with ADHD and epilepsy be given ritalin?
    Boyes C
    Arch Dis Child; 2010 Sep; 95(9):759-61. PubMed ID: 20716679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.